(NASDAQ: CTNM) Contineum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.71%.
Contineum Therapeutics's earnings in 2025 is -$49,831,000.On average, 2 Wall Street analysts forecast CTNM's earnings for 2025 to be -$67,136,670, with the lowest CTNM earnings forecast at -$74,251,346, and the highest CTNM earnings forecast at -$60,021,994. On average, 2 Wall Street analysts forecast CTNM's earnings for 2026 to be -$72,310,979, with the lowest CTNM earnings forecast at -$73,475,199, and the highest CTNM earnings forecast at -$71,146,760.
In 2027, CTNM is forecast to generate -$77,873,362 in earnings, with the lowest earnings forecast at -$77,873,362 and the highest earnings forecast at -$77,873,362.